Why the study?
Comparative clinical outcomes between prediabetes and type 2 diabetes mellitus in older adults with AMI in the era of newer-generation drug-eluting stents are limited.
Do prediabetes and T2DM worsen 2-year clinical outcomes compared to normoglycemia in older adults with AMI treated with newer-generation DES?
Do prediabetes and T2DM worsen 2-year clinical outcomes compared to normoglycemia in older adults with AMI treated with newer-generation DES?
Prediabetes confers a similar risk of 2-year adverse cardiovascular events as T2DM in older adults with AMI undergoing PCI with newer-generation DES, both being worse than normoglycemia.
Prediabetes and T2DM linked to worse 2-year outcomes in older AMI patients; leaves open whether intensified glycemic control improves prognosis.
BACKGROUND: The comparative clinical outcomes between prediabetes and type 2 diabetes mellitus (T2DM) in older adults with AMI in the era of newer-generation drug-eluting stents (DES) are limited. We investigated the 2-year clinical outcomes of these patients. METHODS: A total of 5492 AMI patients aged ≥65 years were classified into three groups according to their glycemic status: normoglycemia (group A: 1193), prediabetes (group B: 1696), and T2DM (group C: 2603). The primary outcome was the occurrence of major adverse cardiac events (MACE), defined as all-cause death, recurrent myocardial infarction (Re-MI), and any repeat revascularization. The secondary outcome was stent thrombosis (ST). RESULTS: The primary and secondary outcomes cumulative incidences were similar between the prediabetes and T2DM groups. In both the prediabetes and T2DM groups, the cumulative incidences of MACE (adjusted hazard ratio [aHR]: 1.373; p = 0.020 and aHR: 1.479; p = 0.002, respectively) and all-cause death or MI (aHR: 1.436; p = 0.022 and aHR: 1.647; p = 0.001, respectively) were significantly higher than those in the normoglycemia group. Additionally, the cumulative incidence of all-cause death in the T2DM group was significantly higher than that in the normoglycemia group (aHR, 1.666; p = 0.003). CONCLUSIONS: In this retrospective study, despite the 2-year clinical outcomes of the patients with prediabetes and T2DM in the older adults were worse than those in the normoglycemia group; they were similar between the prediabetes and T2DM groups. Hence, comparable treatment strategies should be strengthened between prediabetes and T2DM in older adults with AMI. TRIAL REGISTRATION: Retrospectively registered.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: